Zusammenfassung
EAGLE (Economic Assessment of Glycemic Control and Long-term Effects) ist ein Diabetes-Simulationsmodell,
das anhand modernster mathematisch-statistischer Methoden entwickelt und validiert
wurde. Das Modell besteht aus einem epidemiologischen Modul, welches den klinischen
Verlauf des Diabetes anhand verschiedener Einflussfaktoren und Behandlungen simuliert,
und einem gesundheitsökonomischen Modul, welches den klinisch-epidemiologischen Ergebnissen
Kosten zuordnet und modernste ökonomische Analysen ermöglicht. Die mathematische Basis
des Modells bilden Daten aus drei großen Diabetes-Studien: United Kingdom Prospective
Diabetes Study (UKPDS), Diabetes Control and Complications Trial (DCCT) und Wisconsin
Epidemiology Study of Diabetic Retinopathy (WESDR). Im Weiteren wird auf die ausführliche
Bezeichnung des EAGLE-Modells Version 2.0_IV verzichtet und lediglich auf das EAGLE-Modell
verwiesen.
Abstract
EAGLE (Economic Assessment of Glycemic Control and Long-term Effects) is a diabetes
simulation model, which was developed and validated according to state-of-the-art
statistic and mathematic methods. The model consists of an epidemiological module,
which simulates the clinical development of diabetes according to various influence
parameters and treatments, and a health economic module, which assigns costs to the
epidemiological results and permits up to date economic analyses. The mathematic basis
of the model is built on data of three big clinical trials: United Kingdom Prospective
Diabetes Study (UKPDS), Diabetes Control and Complications Trial (DCCT) und Wisconsin
Epidemiology Study of Diabetic Retinopathy (WESDR).
Schlüsselwörter
Krankheitsmodelle - Kosteneffektivität - Diabetes mellitus - Gesundheitsökonomie
Key words
Modelling - simulation - diabetes mellitus - cost effectiveness - health economics
Literatur
- 1
Clarke P M, Gray A M, Briggs A. et al .
UK Prospective Diabetes Study (UKDPS) Group. A model to estimate the lifetime health
outcomes of patients with type 2 diabetes mellitus: the United Kingdom Prospective
Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).
Diabetologia.
2004;
47
1747-1759
- 2
Klein R, Klein B E, Moss S E. et al .
Prevalence of diabetes mellitus in southern Wisconsin.
Am J Epidemiol.
1984;
119
54-61
- 3
The Diabetes Control and Complications Trial Research Group .
The effect of intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control
and Complications Trial Research Group.
N Engl J Med.
1993;
329
977-986
- 4
The UK Prospective Diabetes Study Group .
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK
Prospective Diabetes Study (UKPDS) Group.
Lancet.
1998;
352
837-853
- 5
World Health Organisation life tables for France, Germany, Spain, UK, USA .
http://www3.who.int/whosis/life/life_tables/life_tables.cfm= evidence,life,life_tables&language
= english (last accessed 16.6.2005).
- 6
Stratton I M, Adler A I, Neil H A. et al .
Association of glycaemia with macrovascular and microvascular complications of type
2 diabetes (UKPDS 35): prospective observational study.
Br Med J.
2000;
321
405-412
- 7
Adler A I, Stratton I M, Neil H A. et al .
Association of systolic blood pressure with macrovascular and microvascular complications
of type 2 diabetes (UKPDS 36): prospective observational study.
Br Med J.
2000;
321
412-419
- 8
National Institute for Clinical Excellence (NICE) - Guide to the Methods of Technology
Appraisal (2004). http://www.nice.org.uk/pdf/TAP_Methods.pdf (last accessed: 1.6.2005).
- 9
van Hout B A, Al M J, Gordon G S. et al .
Costs, effects and C/E-ratios alongside a clinical trial.
Health Economics.
1994;
3
309-319
- 10
American D iabetes Association Consensus Panel.
Guidelines for Computer Modeling of Diabetes and Its Complications.
Diabetes Care.
2004;
27
2262-2265
- 11
Analytica International .
EAGLE technical documentation: Auf Anfrage erhältlich.
- 12
Bergemann R.
Charakteristika valider Health-Outcomes Modelle.
Gesundh ökon Qual manag.
2005;
(Suppl 2)
S59-S63
- 13
The Diabetes Control and Complications Trial Research Group .
The effect of intensive diabetes therapy on the development and progression of neuropathy.
The Diabetes Control and Complications Trial Research Group.
Ann Intern Med.
1995;
122
561-568
- 14
Moss S E, Klein R, Klein B E.
The prevalence and incidence of lower extremity amputation in a diabetic population.
Arch Intern Med.
1992;
152
610-616
- 15
Eastman R C, Javitt J C, Herman W H. et al .
Model of complications of NIDDM. I. Model construction and assumptions.
Diabetes Care.
1997;
20
725-734
- 16
Eastman R C, Javitt J C, Herman W H. et al .
Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness
of treating NIDDM with the goal of normoglycemia.
Diabetes Care.
1997;
20
735-744
- 17
Colhoun H M. et al .
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes
in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled
trial.
Lancet.
2004;
364
685-696
Roman N. Casciano, MS
Analytica International, European Office
Untere Herrenstraße 25
79539 Lörrach
Email: rcasciano@de.analyticaintl.com
